Kurnit Katherine C, Steiner Meghan, Lastra Ricardo R, Weroha S John, Cursio John, Lengyel Ernst, Fleming Gini F, Conzen Suzanne D
The University of Chicago Medicine, Department of Obstetrics & Gynecology, Chicago, USA.
The University of Chicago Medicine, Department of Medicine, Chicago, USA.
Gynecol Oncol Rep. 2022 Apr 27;41:100987. doi: 10.1016/j.gore.2022.100987. eCollection 2022 Jun.
Glucocorticoid receptor can be associated with poor prognosis among a variety of solid tumors in the absence of other nuclear hormone receptors. Our objective was to characterize differences in glucocorticoid receptor (GR), estrogen receptor (ER), progesterone receptor (PR), and androgen receptor expression in the sarcomatous versus carcinomatous components of ovarian and uterine carcinosarcomas. Eighteen patients diagnosed with Mullerian carcinosarcoma between May 2009 and August 2014 were included. Nuclear receptor expression was evaluated by immunohistochemistry using whole tissue specimens. Receptor expression was quantified using the H-score. Mean H-scores were compared between the sarcomatous and carcinomatous components of tumors using Wilcoxon signed-rank tests. We found that GR expression was significantly higher in the sarcomatous components than in the carcinomatous components of the cancers (mean H score 144.4 vs 38.9, p = 0.002). Conversely, ER (3.1 vs 63.1, p = 0.002) and PR (1.7 vs 47.2, p < 0.0001) expression were significantly decreased in the sarcomatous component compared to the carcinomatous component. Androgen receptor expression was low overall (0 versus 2.8, p = 0.04). We hypothesize that GR-high, ER/PR-low expression is associated with epithelial to mesenchymal transition in the sarcomatous cells and may serve as a potential therapeutic target.
在缺乏其他核激素受体的情况下,糖皮质激素受体可能与多种实体瘤的不良预后相关。我们的目的是描述卵巢和子宫癌肉瘤的肉瘤成分与癌成分中糖皮质激素受体(GR)、雌激素受体(ER)、孕激素受体(PR)和雄激素受体表达的差异。纳入了2009年5月至2014年8月期间诊断为苗勒管癌肉瘤的18例患者。使用全组织标本通过免疫组织化学评估核受体表达。使用H评分对受体表达进行定量。使用Wilcoxon符号秩检验比较肿瘤的肉瘤成分和癌成分之间的平均H评分。我们发现,癌症的肉瘤成分中GR表达明显高于癌成分(平均H评分144.4对38.9,p = 0.002)。相反,与癌成分相比,肉瘤成分中ER(3.1对63.1,p = 0.002)和PR(1.7对47.2,p < 0.0001)表达明显降低。雄激素受体表达总体较低(0对2.8,p = 0.04)。我们推测GR高、ER/PR低表达与肉瘤细胞中的上皮-间质转化有关,可能是一个潜在的治疗靶点。